Ajinomoto Cambrooke

What Ajinomoto Cambrooke does

Ajinomoto Cambrooke is a US-based therapeutic nutrition company that develops, manufactures, and commercializes prescription and over-the-counter medical foods for patients with inborn errors of protein metabolism (Phenylketonuria, Tyrosinemia, Homocystinuria, Maple Syrup Urine Disease, Isovaleric Acidemia) and for patients with intractable epilepsy requiring ketogenic dietary therapy. The company's technological foundation is glycomacropeptide (GMP) — a naturally occurring low-phenylalanine whole protein derived from whey — developed in collaboration with the University of Wisconsin-Madison and first commercialized as Glytactin for PKU (2005) and Tylactin for Tyrosinemia (2010). Its product portfolio spans GMP-based formula lines (Glytactin and Tylactin in RTD, powder, bar, and hydration formats), amino acid-based formulas (Homactin, Vilactin, Isovactin AA Plus), an extensive low-protein food catalog across 15+ categories, the KetoVie ketogenic formula franchise for epilepsy, and adjacent pediatric and nutritional support brands (Essential Care Jr., EquaCare Jr., ENU Nutrition).

The company was founded in 2000 by Lynn and David Paolella as Cambrooke Foods in Natick, Massachusetts following their children's PKU diagnoses, and was acquired by Ajinomoto Group in 2017, becoming a wholly-owned subsidiary with access to global amino acid supply and international distribution. Revenue is generated through three primary channels: (1) prescription medical formulas sold direct-to-patient via toll-free phone, through DME suppliers, specialty pharmacies, and hospitals on a recurring basis; (2) KetoVie Café ketogenic foods sold without prescription via the US e-commerce storefront (Nexternal-powered) and toll-free ordering; and (3) low-protein foods and pediatric formulas distributed through the US store and essentiallybetter.com. Geographic reach covers the United States, Canada (via distributor Paramed Inc.), the United Kingdom, Germany, and Australia. The company holds OU-D Kosher and ISA Halal certifications on key product lines, and operates with a small specialized team under continued founder involvement in development and patient advocacy.

Name

Ajinomoto Cambrooke

Legal name

Ajinomoto Cambrooke, Inc.

Website

https://cambrookefoods.com

Company type

Private

Founded year

2000

Operating status

Operating

Short description

Ajinomoto Cambrooke develops and commercializes prescription medical foods and ketogenic nutrition products for patients with rare inherited metabolic disorders (PKU, Tyrosinemia, HCU, MSUD, IVA) and intractable epilepsy, using proprietary glycomacropeptide (GMP) technology developed with the University of Wisconsin-Madison.

Ownership category

akta.pro rank

Product category

Specialty Medical Nutrition

NAICS

Food Manufacturing (311), Dried and Dehydrated Food Manufacturing (311423)

SIC

Food And Kindred Products (2000), Medicinal Chemicals & Botanical Products (2833), Bakery Products (2050)

akta.pro primary industry

Medical Foods Manufacturing (Disease-Specific, Clinically Supervised) (AFAKAJAC)

akta.pro secondary industries

Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium) (AFAKAJAD), Special-Diet & Functional Prepared Meals (Keto, Vegan, Gluten-Free, Medical) (CRAHAJAG)

Keywords

• Medical nutrition formulas
• Metabolic disorder foods
• Low protein foods
• Ketogenic diet products
• Glycomacropeptide medical foods

Headquarters

HQ city

Ayer

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Medical Formula Products: Prescription-based medical foods including Glytactin, Tylactin, and amino acid formulas for metabolic disorders. Requires prescription from physician or dietitian. Sold directly via phone or through DME/specialty pharmacies/hospitals.
2. Ketogenic Foods (KetoVie Café): Ketogenic diet foods and formulas available without prescription. Sold through US store and toll-free ordering.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Ajinomoto Cambrooke develops, manufactures, and commercializes prescription and non-prescription medical nutrition products—including glycomacropeptide (GMP)-based formulas, amino acid formulas, ketogenic formulas, and a broad line of low-protein foods—for patients with inborn errors of metabolism (PKU, Tyrosinemia, HCU, MSUD, IVA) and intractable epilepsy. Products are sold directly to patients, through healthcare professionals, and via DME suppliers, specialty pharmacies, and hospitals.

Product overview

Ajinomoto Cambrooke is a therapeutic medical nutrition company offering specialized products for patients with metabolic disorders including Phenylketonuria (PKU), Tyrosinemia (TYR), Homocystinuria (HCU), Maple Syrup Urine Disease (MSUD), Isovaleric Acidemia (IVA), and epilepsy requiring ketogenic diets. The product portfolio centers on three core formula lines—Glytactin (for PKU, using proprietary glycomacropeptide/GMP technology), Tylactin (for TYR, also GMP-based), and Amino Acid formulas (Homactin AA Plus, Isovactin AA Plus, Vilactin AA Plus for HCU/MSUD/IVA)—supplemented by extensive Low Protein Foods across 15+ food categories, KetoVie ketogenic formulas and KetoVie Café foods, ENU Nutrition shakes, and Essential Care Jr./EquaCare Jr. pediatric products. The company was founded in 2000 and acquired by Ajinomoto in 2017.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Glytactin helps stabilize Phe levels throughout the day, eliminating spikes and troughs seen with alternative PKU preparations
• +3 more outcomes

Named customers4 records

Segments6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• University of Wisconsin, MadisoncoreStrategic or Co-development PartnerGroundbreaking collaboration with scientists at the University of Wisconsin, Madison resulted in development of Glytactin with glycomacropeptide (GMP), an innovative protein source derived from whey.
• New England Connection for PKU and Allied Disorders (NECPAD)minorStrategic or Co-development PartnerLynn Paolella became a founding member of NECPAD alongside dedicated mothers and clinicians. The organization provided support and advocacy for the PKU community.
• Paramed Inc.coreChannel Partner/ Reseller/ DistributorCanadian distributor for ordering Cambrooke products. Orders can be sent to [email protected] or by Fax to 1-844-395-2396. Canadian Sales Team available at 1-800-793-4713.
• Disney World/LandminorStrategic or Co-development PartnerPartnership to provide low-protein food options at Disney theme parks, allowing PKU individuals and families to have dining options during visits.
• Sea World and Cruise LinesminorStrategic or Co-development PartnerPartnerships to offer low-protein foods on cruise ships and at Sea World, expanding dining options for individuals with metabolic disorders.
• Boston Children's HospitalminorStrategic or Co-development PartnerLynn Paolella received support and guidance from Boston Children's Hospital and Fran Rohr, RD in particular, for managing her children's PKU and connecting with other families.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Nutricia (Danone): Danone's medical nutrition division is a leading global provider of metabolic disorder formulas, including PKU products (PKU Anamix, Lophlex). Directly competes with Cambrooke in disease-specific medical foods across the same patient populations and distribution channels.
• Vitaflo (Nestlé Health Science): Specializes in medical nutrition for inherited metabolic disorders and ketogenic diets, with products directly competing against Cambrooke's Glytactin/Tylactin and KetoVie lines. Operates in the same clinical specialty channels and disease categories.
• Applied Nutrition: Produces low-protein medical foods and PKU/TYR formulas. Direct overlap with Cambrooke's low-protein food lines and metabolic formula portfolio in the US and international markets.
• Promin (low-protein foods): UK-based specialist in low-protein foods for PKU and renal conditions. Direct competitor to Cambrooke's low-protein food line in Europe and export markets, with overlapping product categories (breads, pasta, baking mixes).

Broad incumbents

• Abbott Nutrition: Major diversified medical nutrition player offering metabolic formulas and pediatric nutrition products (e.g., Cyclinex, Phenex). Competes with Cambrooke in PKU and metabolic disorder formulas but as part of a much broader hospital and consumer nutrition portfolio.
• Mead Johnson Nutrition (Reckitt): Long-established pediatric and metabolic nutrition company (PurAmino, BCAD). Overlaps with Cambrooke in metabolic formulas for infants and children but operates a broader infant nutrition franchise.
• Nestlé Health Science: Parent of Vitaflo and a major provider of medical nutrition across metabolic, GI, and pediatric conditions. Competes with Cambrooke across multiple product categories and geographies as part of a large healthcare nutrition portfolio.

Emerging players

• BioMarin Pharmaceutical: Markets Palynziq (pegvaliase) and previously pegvaliase/bioactive therapies for the same PKU patient population Cambrooke serves. Represents a therapy-based competitive threat rather than direct formula competition, but addresses the same patients and prescribers.
• Recordati Rare Diseases: Markets Carglumic acid (Carbaglu) and other rare metabolic disease therapies. Serves overlapping rare metabolic patient populations (e.g., organic acidurias, urea cycle disorders) and shares clinical specialist relationships with Cambrooke.

Others

• Galen Medical: Distributes medical foods and metabolic formulas to pharmacies and clinics in select markets. Operates as an adjacent channel/partner rather than a direct formula manufacturer, but interacts with the same patient and prescriber ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/cambrookefoodsinc
• Facebookfacebook.com/CambrookeTherapeutics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ajinomoto Cambrooke